25
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Cytotoxicity of alpha -particle-emitting 5-\[211At]astato-2-deoxyuridine in human cancer cells

Pages 79-90 | Published online: 03 Jul 2009

References

  • BARANOWSKA-KORTYLEWICZ, J., MAKRIGIORGOS, G. M., VAN DEN ABBELE, A. D., BERMAN, R. M., ADELSTEIN, S. J. and KASSIS, A. I.RT, 1991, 5[123Thodo-2-deoxyuridine in the radiotherapy of an early ascites tumour model. International Journal of Radiation Oncology Biology Physics. 21, 1541–1551.
  • BIGNER, D. D., BROWN, M., COLEMAN, R. E., FRIEDMAN, A. H., FRIEDMAN, H. S., McLENDON, R. E., BIGNER, S. H., WIKSTRAND, C. J., PEGRAM, C. N., KERBY, T. and ZALUTSKY, M. R., 1995, Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 8106 and anti-chondroitin proteoglycan sulfate Mel-14 F(abl—A preliminary report. Journal of N euro- Oncology 24, 109–122.
  • BIGNER, S. H., FRIEDMAN, H. S., BIEGEL, J. A., WIKSTRAND, C. J., MARK, J., GEBHARDT, R., ENG, L. F. and BIGNER, D. D., 1986, Specific chromosomal abnormalities charac-terize four established cell lines derived from malignant human gliomas. Acta N europathologia, 72, 86–97.
  • BLOOMER, W. and ADELSTEIN, S. J., 1981, Iodine-125 cytotox-icity: implication for the therapy and estimation of radi-ation risk. International J ournal of Nuclear M edicine and Biology, 8, 171–178.
  • BLOOMER, W. D., MCLAUGHLIN, W. H., WEICHSELBAUM, R. R., HANSON, R. N., ADELSTEIN, S. J. and SEITZ, D. E., 1981,
  • The role of subcellular localization in assessing the cyto-toxicity of iodine-125 labeled iododeoxyuridine, iodota-moxifen, and iodoantipyrine. Journal of R adioanaly Beal Chemistry, 65, 209–221.
  • BRADLEY, E. W., CHAN, P. C. and ADELSTEIN, S. J., 1975, The radiotoxicity of iodine-125 in mammalian cells 1. Effects of the survival curve of radioiodine incorporated into DNA. Radiation Research, 64, 555–563.
  • BROWN, M. T., COLEMAN, R. E., FRIEDMAN, A. H., FRIEDMAN, H. S., MCLENDON, R. E., REIMAN, R., FELSBERG, G. J., TIEN, R. D., BIGNER, S. H., ZALUTSKY, M. R., ZHAO, X. G., WIKSTRAND, C. J., PEGRAM, C. N., HERNDON II, J. E., VICK, N. A., PALEOLOGOS, N., FREDERICKS, R. K., SCHOLD, JR., S. C. and BIGNER, D. D., 1996, Intrathecal 131I-labeled anti-tenascin monoclonal antibody 8106 treatment of patients with leptomeningeal neoplasms or primary brain tumour resection cavities with subarach-noid communication: phase I trial results. Clinical Cancer Research, 2, 963–972.
  • FORD, J. R. and TERZAGHI-HOWE, M., 1993, Effects of 2101)0 alpha particles on survival and preneoplastic transforma-tion of primary rat tracheal epithelial cells irradiated while in suspension or in the intact tissue. Radiation Research, 136, 89–96.
  • HALL, E. J., 1994, Radio biology for the R adiologist, 4th edn. (Philadelphia: J.B. Lippincott).
  • HOWELL, R. W., 1992, Radiation spectra for Auger-electron emitting radionuclides: Report No. 2 of AAPM nuclear medicine task group No. 6. Medical Physics, 19, 1371–1376.
  • Humm, J. L. and CHIN, L. M., 1993, A model of cell inactivation by a-particle internal emitters. Radiation Research, 134, 143–150.
  • Humm, J. L., BAGSHAWE, K. D., SHARMA, S. K. and BOXER, G., 1991, Tissue dose estimates following the selective uptake of 125IUdR and other radiolabelled thymidine precursors in resistant tumours. British Journal of Radio toy, 64, 45–49.
  • HYMER, W. C. and KUFF, E. L., 1964, Isolation of nuclei from mammalian tissues through the use of Triton X-100. Journal of H istochemistry and Cytochemistiy, 12, 359–363.
  • KASSIS, A. I. and ADELSTEIN, S. J., 1982, Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian Cells. Radiation Research, 90, 362–373.
  • KASSIS, A. I., FAYAD, F., KINSEY, B. M., SASTRY, K. S. R., TAUBE, R. A. and ADELSTEIN, S. J., 1987a, Radiotoxicity of 1251 in mammalian cells. Radiation Research, 111, 305–318.
  • KASSIS, A. I., SASTRY, K. S. and ADELSTEIN, S. J., 1987b, Kinetics of uptake, retention, and radiotoxicity of 125IUDR in mammalian cells: Implication of localized energy deposition by Auger processes. Radiation Research, 109, 78–89.
  • KASSIS, A. I., VAN DEN ABBEELE, A. D., WEN, P. Y. C., BARANOWSKA-KORTYLEWICZ, J., AARONSEN, R. A., DESISTO, W. C., LAMPSON, L. L., . BLACK, P. MCL. and ADELSTEIN, S. J., 1990, Specific uptake of the Auger electron-emitting thymidine/ analog 5- [123/1251] iod o-2 deoxyuridine in rat brain tumours: diagnostic and thera-peutic implications in humans. Cancer Research, 50, 5199–5203.
  • KNOL, J. A., WALKER, S. C., ROBERTSON, J. M., YANG, Z., DEREMER, S., STETSON, P. L., ENSMINGER, W. D. and LAWRENCE, T. S., 1995, Incorporation of 5-bomo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Research, 55, 3687–3691.
  • LARSEN, R. H. and BRULAND, 0. S., 1995, Radiolysis of radioim- munoconjugates. Reduction in antigen-binding ability by a-particle radiation. Journal of Labelled Compounds and R adiopharmaceutica Is, 36, 1009–1018.
  • LARSEN, R. H., WIELAND, B. W. and ZZLUTSKY, M. R., 1996, Evaluation of an internal target for the production of astatine-211 via the 255Bi(a,2n)211At reaction. Applied Radiation and Isotopes, 47, 135–143.
  • MAKRIGIORGOS, G. M., KASSIS, A. I., BARANOWSKA-KORTYLEWICZ, J., MCELVANY, K. D., WELCH, M. J., SASTRY, K. S. R. and ADELSTEIN, S. J.7 1989, Radiotoxicity of 5- [123I]Iodo-2'-deoxyuridine in V79 cells: a comparison with 5- [125I]Iodo-2'-deoxyuridine. Radiation Research, 118, 532–544.
  • MARIANI, G., CET, A., COLLECCHI, P., BARANOWSKA-KORTYLEWICZ, J., VAN DEN ABBEELE, A. D., DI LUCA, L., DI STEFANO, R., VIACAVA, P., FERDEGHINI, E. M., DI SACCO, S., SALVADORI, P. A., BEVILACQUA, G., ADELSTEIN, S. J., MOSCA, F. and KASSIS, A. 1.7 1993, Tumour targeting in vivo and metabolic fate of 5- [iodine-125] iodo-2-deoxyu ridine following intratu mou - ral injection in patients with colorectal cancer. Journal of Nuclear Medicine, 34, 1175–1183.
  • PEREZ, L. A., DOMBKOWSKI, D., EFIRD, J., PFEFFER, F. and SUIT, H. D., 1993, Cell proliferation kinetics in human tumour xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other prolif- eration measurements. cancer Research, 55, 392–398.
  • RAO, D. V., NARRA, V. R., HOWELL, R. W. and SASTRY, K. S. R., 1990, Biological consequence of nuclear versus cytoplasmic decays of 1251: cysteamine as a radioprotector against Auger cascades in vivo. Radiation Research, 124, 188–193.
  • ROSSLER, K. G. and ETCH, G., 1989, Nuclear recoils from 211At decays. Radio chim ica A cta, 477 87–89.
  • STRICKLAND, D. K., VAIDYANATHAN, G. and ZALUTSKY, M. R.7 1994, Cytotoxicity of a- particle-emitting m-[211At] astatob enzylguanidine on human neu rob lastom a cells. cancer Research, 54, 5414–5419.
  • THACKER, J., STRETCH, A. and STEVENS, M. A.7 19827 Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. II. Chinese hamster V79 Cells. International ournal of Nuclear Medicine and Biology, 9, 167–171.
  • VAIDYANATHAN, G., LARSEN, R. H. and ZALUTSKY, M. R.71996, [211At] a stato -2deoxyu ridine, an a-particle -emittingendoradiotherapeutic agent undergoing DNA incorpora-tion. Cancer Research, 56, 1204–1209.
  • WEBER, D. A., ECKERMAN, K. F., DILLMAN, L. T. and RYMAN, J. C., 1989, MIRD: Radionuclide Data and Decay Schemes (New York: Society of Nuclear Medicine).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.